Cargando…
Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy
BACKGROUND/AIM: To evaluate relationships between subretinal fluid (SRF), macular atrophy (MA) and visual outcomes in ranibizumab-treated neovascular age-related macular degeneration (nAMD). METHODS: This post hoc HARBOR trial (NCT00891735) analysis included ranibizumab-treated (0.5 or 2.0 mg, month...
Autores principales: | Zarbin, Marco A, Hill, Lauren, Maunz, Andreas, Gliem, Martin, Stoilov, Ivaylo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606534/ https://www.ncbi.nlm.nih.gov/pubmed/34039560 http://dx.doi.org/10.1136/bjophthalmol-2020-318688 |
Ejemplares similares
-
Predicting vision gains with anti-VEGF therapy in neovascular age-related macular degeneration patients by using low-luminance vision
por: Frenkel, Ronald E P, et al.
Publicado: (2016) -
Hyperreflective Foci and Subretinal Fluid Are Potential Imaging Biomarkers to Evaluate Anti-VEGF Effect in Diabetic Macular Edema
por: Qin, Shiyue, et al.
Publicado: (2021) -
Macular Atrophy Development and Subretinal Drusenoid Deposits in Anti-Vascular Endothelial Growth Factor Treated Age-Related Macular Degeneration
por: Zarubina, Anna V., et al.
Publicado: (2017) -
Acquired Vitelliform Macular Degeneration: Characteristics and Challenges of Managing Subretinal Fluid
por: Juliano, Joseph, et al.
Publicado: (2021) -
Aqueous humor analyses of diabetic macular edema patients with subretinal fluid
por: Kwon, Jin-woo, et al.
Publicado: (2021)